Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, ...

Haemonetics (HAE) recently completed the sale of its whole blood assets to GVS, S.p.A ("GVS"), a leading provider of advanced filtration solutions for highly critical applications. With this development, GVS now has the company’s portfolio of proprietary whole blood collection, processing and filtration solutions, along with its manufacturing facility in Covina, CA and related equipment and assets at its Tijuana, Mexico manufacturing site.The transaction was announced last month and comprises a total cash c ...

BOSTON, Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed the previously announced sale of its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. In connection with the closing of this transaction, GVS has acquired Haemone ...

BOSTON, Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025. The call can be accessed via teleconference at: Q3 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will ...

BOSTON, Jan. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 5:15 pm Pacific Time.The public may access Mr. Simon's presentation live via audio webcast at: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58190-haemonetics-corporation/webcast?gpu_only=true&kiosk=true  The live webcast can also be accessed under the Events ...

Haemonetics Corporation’s (HAE) growth in the fiscal second quarter of 2025 can be attributed to the strong potential of the Plasma franchise. The robust uptake of the NexSys PCS system bodes well for its long-term growth. Strong financial stability also buoys optimism. Meanwhile, headwinds from fierce competition pose concerns for Haemonetics’ operations.In the past year, this Zacks Rank #2 (Buy) company’s shares have lost 12.3% against the industry’s 11.2% growth and the S&P 500 composite’s 25.7% rise.The ...

Haemonetics (HAE) has been on a downward spiral lately with significant selling pressure. After declining 11.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock i ...

Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision ...

If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 yearsMARBURG, Germany, Dec. 13, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorization for garadacimab as a once-monthly p ...

Haemonetics (HAE) closed the last trading session at $85.26, gaining 13.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $109 indicates a 27.8% upside potential.The average comprises eight short-term price targets ranging from a low of $85 to a high of $125, with a standard deviation of $13.11. While the lowest estimate indicates a decline of 0.3% from the current price level, th ...